Intrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature

Simple item page
dc.contributor.authorBidikian, Aram H.
dc.contributor.authorBazarbachi, Ali Abdul Hamid
dc.contributor.authorHourani, Roula G.
dc.contributor.authorEl-Cheikh, Jean
dc.contributor.authorAbou Dalle, Iman
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDiagnostic Radiology
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:01:50Z
dc.date.available2025-01-24T12:01:50Z
dc.date.issued2021
dc.description.abstractThe regular administration of intrathecal chemotherapy has significantly reduced the risk of central nervous system leukemia in patients with acute lymphoblastic leukemia. We report the case of 28-year-old man who developed intrathecal methotrexate induced myelopathy; a rare but serious side effect of intrathecal chemotherapy. In the light of absent effective treatment strategies, description of the case, along with reviewing similar cases published in the literature will help shed a light on the possible pathophysiologic mechanisms behind this injury. To this date, there are no specific clinical, biochemical and imaging signs that would allow timely detection of intrathecal methotrexate induced myelopathy. This in turn is causing delayed treatment of this injury, resulting in significant morbidity and mortality. © 2021 Elsevier Masson SAS
dc.identifier.doihttps://doi.org/10.1016/j.retram.2021.103296
dc.identifier.eid2-s2.0-85107912299
dc.identifier.pmid34139603
dc.identifier.urihttp://hdl.handle.net/10938/31466
dc.language.isoen
dc.publisherElsevier Masson s.r.l.
dc.relation.ispartofCurrent Research in Translational Medicine
dc.sourceScopus
dc.subjectAcute lymphoblastic leukemia
dc.subjectIntrathecal
dc.subjectMethotrexate
dc.subjectMyelopathy
dc.subjectAdult
dc.subjectHumans
dc.subjectMale
dc.subjectPrecursor cell lymphoblastic leukemia-lymphoma
dc.subjectSpinal cord diseases
dc.subjectCyanocobalamin
dc.subjectFolinic acid
dc.subjectGabapentin
dc.subjectMethylprednisolone
dc.subjectArticle
dc.subjectBacteremia
dc.subjectBone marrow
dc.subjectCancer regression
dc.subjectCase report
dc.subjectCerebrospinal fluid examination
dc.subjectClinical article
dc.subjectDermatome
dc.subjectDrug overdose
dc.subjectElectromyography
dc.subjectFolic acid blood level
dc.subjectHuman
dc.subjectLumbar puncture
dc.subjectMotoneuron
dc.subjectNeurologic examination
dc.subjectNuclear magnetic resonance imaging
dc.subjectParaplegia
dc.subjectPhysiotherapy
dc.subjectPneumonia
dc.subjectPolymerase chain reaction
dc.subjectSeptic shock
dc.subjectSkin tingling
dc.subjectSpinal cord disease
dc.subjectThrombocytopenia
dc.subjectUrine retention
dc.subjectWeakness
dc.titleIntrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-2582.pdf
Size:
539.51 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine
Diagnostic Radiology